Versor Investments LP Takes $47.04 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Versor Investments LP bought a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing with the Se
Brinker Capital Investments LLC Buys Shares of 3,167 Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Brinker Capital Investments LLC bought a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the second quarter, according to the company in its most recent Form 13F filing w
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares Sold by Amalgamated Bank
Amalgamated Bank cut its position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) by 7.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Given Average Rating of "Hold" by Brokerages
Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) has received an average rating of "Hold" from the twelve brokerages that are covering the stock, Marketbeat reports. Eight research analys
ProShare Advisors LLC Sells 3,250 Shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
ProShare Advisors LLC reduced its position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) by 19.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 13,760 shares of th
Turning Point Therapeutics (NASDAQ:TPTX) Sees Strong Trading Volume
Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) shares saw unusually-high trading volume on Tuesday . Approximately 50,472 shares were traded during trading, a decline of 94% from the pr
News On Turning Point Therapeutics Inc. (TPTX) Now Under BMY
News On Turning Point Therapeutics Inc. (TPTX) Now Under BMY
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Press Release: Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio NEW YORK--(BUSINESS WIRE)--August 17, 2022-- Bristol Myers Squibb (NYSE:BMY) announce
Turning Point Therapeutics (NASDAQ:TPTX) Sees Unusually-High Trading Volume
Shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) saw strong trading volume on Tuesday . 50,472 shares changed hands during mid-day trading, a decline of 94% from the previous ses
Bristol Myers' $4.1B Turning Point Acquisition Gets Clearance in US, Germany, Set to Close
Bristol Myers Squibb's (NYSE:BMY) $4.1B acquisition of Turning Point Therapeutics (NASDAQ:TPTX) received antitrust clearance in the U.S. and Germany. New York-based Bristol Myers said that while the w
Bristol Myers, Turning Point See Deal Closing Aug. 17 >BMY
Bristol Myers, Turning Point See Deal Closing Aug. 17 >BMY
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance From Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the rec
IndexIQ Advisors LLC Purchases New Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
IndexIQ Advisors LLC purchased a new stake in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the first quarter, according to the company in its most recent filing with the Securities
SVB Leerink Equities Analysts Decrease Earnings Estimates for Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) – SVB Leerink reduced their Q3 2022 EPS estimates for Turning Point Therapeutics in a research report issued to clients and investors on
JMP Securities Remains a Hold on Turning Point Therapeutics (TPTX)
JMP Securities analyst Silvan Tuerkcan maintained a Hold rating on Turning Point Therapeutics (TPTX – Research Report) today. The company's shares closed yesterday at $75.04. Tuerkcan covers the Healt
Turning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly Earnings Results
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) announced its quarterly earnings data on Monday. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate
Turning Point Therapeutics GAAP EPS of -$2.48 misses by $0.78, revenue of $0.12M misses by $2.15M
Turning Point Therapeutics press release (NASDAQ:TPTX): Q2 GAAP EPS of -$2.48 misses by $0.78. Revenue of $0.12M (-97.7% Y/Y) misses by $2.15M.
Turning Point Thera 2Q Rev $119,000 >TPTX
Turning Point Thera 2Q Rev $119,000 >TPTX
Turning Point Thera 2Q Loss/Shr $2.48 >TPTX
Turning Point Thera 2Q Loss/Shr $2.48 >TPTX
No Data